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Background: The malaria rapid diagnostic tests (RDTs) are now widely used in the world. Compared to Plasmodium
falciparum, a poor sensitivity of RDTs was reported against Plasmodium vivax based on the adopted antibody against
pan-Plasmodium antigen lactate dehydrogenase (pLDH) or aldolase. Levels of pLDH were measured from patient
with P. vivax, and the correlations between the levels of pLDH and the sensitivities of RDTs were analysed among
Republic of Korea (ROK) isolates.
Methods: Three RDTs, OptiMAL test, SD BIOLINE Malaria Ag P.f/Pan test, Humasis Malaria Pf/Pan antigen test, and the
Genedia pLDH antigen ELISA were performed with blood samples from 152 febrile patients and 100 healthy controls.
Results: Three malaria RDTs revealed sensitivities between 85.5 (131/152) and 86.8% (132/152) with highest sensitivity
for the detection of P.vivax by pLDH antigen ELISA test (145/152, 95.4%) in comparison to traditional microscopy
using Giemsa–stained slides. None of the healthy control tested positive by three RDTs or ELISA, indicating 100%
specificity in their respective test. Levels of pLDH among Korean P. vivax isolates ranged between 0 ng/mL and
22,387.2 ng/mL (mean ± standard deviation 3,917.5 ± 6,120.9 ng/mL). The lower detection limits of three RDTs were
between 25 and 50 ng/mL with artificially diluted samples. The moderate degree of correlation was observed
between parasitaemia and concentrations of pLDH (r = 0.4, p < 0.05).
Conclusion: The pLDH levels of P. vivax are the main explanation for the variations in the performance of pLDH-based
RDTs. Therefore, comparing sensitivities of RDT may need to include targeted biomarker value of patients.
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Malaria remains to be one of the most difficult infectious
diseases to control. Even though many new efforts are be-
ing made to eradicate the disease, the incidences and
prevalence of malaria does not decrease and is worsening
in some incidents [1]. Early diagnosis and treatment are es-
sential for reducing its morbidity and mortality and for this
reason, rapid and accurate diagnosis of malaria is import-
ant. The Giemsa-stained thin and thick peripheral blood
smears and PCR methods are acceptable as gold standard,
but the relative long assay time and the requirement of* Correspondence: malarim@korea.ac.kr
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reproduction in any medium, provided the orstaff training or special instruments are limitations that are
not easy to overcome [2,3]. Hence, effective and rapid
immunochromatographic tests with simple procedures
were developed for diagnosing malaria [4,5]. Even though
the immunochromatography-based kit has proven to be an
easy and rapid method for the clinical diagnosis of malaria
by inexperienced personnel, few antigens were considered
as targets for adoption in malaria rapid diagnostic tests
(RDTs) until now.
The major target antigens of malaria RDTs were spe-
cific histidine-rich protein 2 (PfHRP-2), and Plasmodium
lactate dehydrogenase in Plasmodium falciparum and
pan-specific Plasmodium lactate dehydrogenase and al-
dolase were used for detecting other human Plasmodium
species. While sensitivities of currently available malaria
assay kits in the market would fluctuate by field conditions,d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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with reactive antibodies to pan-Plasmodium antigen lactate
dehydrogenase (pLDH) or aldolase was reported in com-
parison to RDTs for P. falciparum [2,6-8]. The sensitivity
of malaria RDTs depended usually on parasitaemia of pa-
tients, however, a common discrepancy was observed in
treatment monitoring cases with gametocytaemia [9].
Monitoring the treatment outcomes through pLDH-based
tests could be limited [9].
Among malaria RDTs, pLDH-based malaria RDTs
present better sensitivities, corresponding well to the
respective levels of parasitaemia. The levels of pLDH
reflect the presence of metabolically viable P. vivax par-
asites, since pLDH usually disappear rapidly within
three to five days in the body [10]. Hence, pLDH-based
malaria RDTs could also be used to monitor patient re-
sponses to anti-malarial therapy. Overall, pLDH is the
preferred target in developing many malaria RDTs in
the field. While the performances of malaria RDTs were
evaluated according to parasitaemia levels of patients in
many studies [10-14], it should be noted that the target of
rapid kit is antigens, not parasite itself. Until now, distribu-
tion of pLDH levels in P.vivax infected patients and sensi-
tivities of currently available malaria RDTs were not
reported. In addition, the association from RDT results be-
tween pLDH levels and parasitaemia was not evaluated.
In the present study, levels of pLDH with pLDH spe-
cific ELISA test were measured in diagnosed patients
with P. vivax in comparison with three simultaneous
RDT tests. The results of both RDT and pLDH ELISA
assays for P. vivax were analysed and compared against
parasitaemia levels from Giemsa-stain microscopy for
calculating the detection limit of pLDH-based RDT kits.
Methods
Subjects
A total of 252 samples, including 100 healthy controls,
were collected between April 2009 and November 2012
at Korea University Hospital, Republic of Korea (ROK).
Patients (n = 152) had fever or a recent history of fever
within a week of their return from malaria-endemic re-
gions. All patients and control subjects gave their in-
formed written consent to participate in the study. This
study was approved by the Ethical Committee of the
Korea University Guro Hospital.
Thick and thin blood films were prepared for the diag-
nosis of malaria. The species and density of the plasmo-
dial parasites were blindly determined by two experts
in malaria diagnosis, using microscopic examination of
Giemsa-stained thick and thin blood films. Parasitaemia
was indirectly calculated by counting the parasite numbers
per 200 white blood cells (WBC) in blood film, and the
WBC counts from the automatic blood cell counter (Cell-
Dyn 4000, Abbott Diagnostics, USA).Polymerase chain reaction (PCR)
Genomic DNA was extracted from frozen pellets using a
blood genomic DNA extraction kit (Bio-Solution, ROK)
and stored at −80°C. Circumsporozoite protein (CSP)
genes of P. vivax (Belem strain, M11926) were ampli-
fied as previously described [8].
Rapid diagnostic tests for malaria
The three RDTs, OptiMAL test, SD BIOLINE Malaria
Ag Pf/Pan test and Humasis Malaria Pf/Pan antigen test,
were used in this study. Humasis Malaria Pf/Pan antigen
test kits (AMAL-7025) were provided by the manufacturer
for the evaluation, and the OptiMAL-IT test (710024) and
SD BIOLINE Malaria Ag Pf/Pan test (05FK60) kits were
purchased from BioRad Inc (Hercules, USA) and SD Inc
(Seoul, ROK), respectively. OptiMAL test incorporated
pLDH from P. falciparum and pan-Plasmodium-specific
pLDH from P. vivax, as major specific target antigens. The
other two tests used HRP-II from P. falciparum and pan-
Plasmodium-specific pLDH from P. vivax for the specific
target antigens. The assays were performed following each
manufacturer’s instructions. All RDTs were read by differ-
ent technicians, who were blinded against the results from
the other diagnostic techniques and RDTs. Detection limit
of pLDH and parasitaemia in three RDTs from five individ-
ual kits was determined from artificially diluted P. vivax
samples with known parasitaemia (8,700/μL) and pLDH
level (5,000 ng/ml).
pLDH level measurement by pLDH antigen ELISA test
Genedia malaria antigen ELISA test (Green Cross Co,
ROK) was provided for the evaluation. The ELISA test was
based on the quantification of pLDH in a whole blood
sample with immobilized pLDH-specific capture antibody
on 96-well plates. The ELISA test was performed, as
recommended by the manufacturer. Briefly, 50 mL of
EDTA whole blood and controls were added to each well
with 100 mL of diluent. After one-hour incubation at 37°C,
unbound materials were washed away with PBS-Tween 20,
and 50 mL peroxidase-conjugated goat anti-pLDH (1:101
dilution) was added to each well. The supplied recom-
binant pLDH antigen on the kit was diluted serially
from 2,500 to 0.02 ng/mL as positive controls and refer-
ence standards. After 30 min incubation at 37°C, the excess
peroxidase-conjugated antibody was washed away three
times with 500 mL PBS/0.05% Tween-20 (PBS/Tween),
and the chromogenic signal was developed with addition
of 200 mL tetramethylbenzidine-dimethyl sulphoxide
(TMB). Following 20-min incubation at 37°C, the reac-
tion was stopped by adding 20 μl of 5 N H2SO4. Ab-
sorbance at 450 nm was read using an ELISA reader
(Behring Elisa Processor III, Siemens, Germany). Each sam-
ple was tested in duplicate, and the optical density (OD)
values were averaged. The background value at wavelength
Jang et al. Malaria Journal 2013, 12:181 Page 3 of 6
http://www.malariajournal.com/content/12/1/181at 650 nm was subtracted from the OD values at 450 nm
for each sample.
The obtained OD values of the standard references
were plotted against their concentrations, either on
semi-logarithmic graph paper or using an automated
method. The concentrations of the samples were read
directly from the standard reference curve. Samples with
higher concentrations than the highest standard refer-
ence were diluted, re-assayed, and calculated according
to the dilution factor. For the data analysis of dichotom-
ous groups, cut-off value (CO) for the positive ELISA
signals was set at 0.1 plus mean OD of negative control
(as recommended by manufacturer). S/CO value was
counted as S divided by CO. If S/CO value was greater or
less than 1.0 (≥1.0 or <1.0), the samples were interpreted
as positive or negative, respectively.
Results
During the study period, 152 patients and 100 healthy con-
trols were enrolled and diagnosed for malaria parasites by
PCR and microscopic examination of Giemsa-stained
blood smear. CSP genes were successfully amplified from
parasite genomic DNA from 152 patients. Mean (±SD)
parasitaemia level was 3954.1 ± 3712.5/μL with range be-
tween 2.0 and 19,382.0/μL, and mean (±SD) pLDH level of
P. vivax infected patients was 3,971.5 ± 6120.9 ng/mL with
range between 0 and 22,387.2 ng/ml (Table 1). Major
pLDH levels of P. vivax (38.8%, 59/152) fell between 500–
5,000 ng/mL (mean ± SD, 1702.0 ± 1001.5 ng/mL), and
the second frequent level was over 5,000 ng/mL (25.1%,
40/152). Thirty seven cases (20.1%) revealed extremely
low pLDH levels, less than 50 ng/mL. In healthy controls,
pLDH was not detected. The lowest detectable level of
pLDH antigen ELISA was 6.3 ng/mL, and lowest parasit-
aemia level of patients detected by pLDH antigen ELISA
was five parasites/μL in clinical samples. Direct correlation
was observed between pLDH level and parasitaemia (r =
0.4, p < 0.05) (Figure 1). However, some discrepancies were
observed between parasitaemia and pLDH levels (Figure 1).
Seven cases of P. vivax patients with parasitaemia over
1,000/μL presented very low pLDH levels (<100 ng/mL).Table 1 The sensitivities of rapid diagnostic tests compared a
infection
Sensitivity
pLDH (ng/mL) pLDH Ag ELISA(%) SD Bioline (%) OptiM
>5,000 (n = 40) 40/40 (100.0) 40/40 (100.0) 40/40
500-5,000 (n = 59) 59/59 (100.0) 59/59 (100.0) 59/59
50-500 (n = 16) 16/16 (100.0) 14/16 (87.5) 14/16
<50 (n = 37) 30/37 (81.1) 19/37 (55.5) 18/37
Total (n = 152) 145/152 (95.4) 132/152(86.8) 131/15
Healthy control 100 0/100 0/1The diagnostic sensitivity of pLDH antigen ELISA was
95.4% (145/152) among microscopy-positive cases with
100% specificity (0/100), which was superior to three
malaria RDTs. OptiMAL test, SD BIOLINE Malaria Ag
P.f/Pan test, and Humasis Malaria Pf/Pan antigen test
had sensitivity of 85.5% (131/152), 86.8% (132/152), and
86.8% (132/152) with each 100% specificity (0/100), re-
spectively (Table 1).
From five repeated test by each kit, detection limits of
pLDH in three RDTs were determined as 50 ng/mL for
OptiMAL test and 25 ng/ml for SD BIOLINE Malaria
Ag P.f ⁄ Pan test and Humasis Malaria P.f ⁄ Pan antigen
test with artificially diluted samples (Table 2). The pLDH
levels in negative cases by all three RDTs (n = 19) were
approximately 19.7 ± 28.4 ng/mL, while values of parasit-
aemia were observed at 348.8 ± 602.4/μL. In all positive
cases, much higher levels of pLDH from RDTs were ob-
served at 4,651.2 ± 6374.1 ng/mL with corresponding
parasitaemia of 4,586.1 ± 6,666.8/μL (Table 3).
Discussion
Malaria diagnostic tests should be easy to perform and
the interpretation of the results by examiners needs to
be simple, however, in many RDTs sensitivities and spec-
ificities fluctuate in various field settings. The evalua-
tions of pLDH-based RDTs for P. vivax indicate that
quality and performance are not satisfactory due to low
sensitivity. Poor manufacturing conditions or inadequate
precautions in transportation and storage of RDTs result
in low sensitivity and reproducibility [11,12].
Even though patient parasitaemia levels are the most
important determining factor for sensitivity of RDTs,
several exceptional cases could not be explained by para-
sitaemia factors only. Traditionally, the performances of
malaria RDTs are analysed by comparing the value with
the parasitaemia levels from microscopic examinations.
Microscopy-based evaluations reveal frequent limitations
due to incorrect interpretation results dependent on ex-
aminers’ training and experience. Hence, the measured
value of pLDH by ELISA could be more objective than
the parasitaemia value, and the value of pLDH couldgainst the levels of pLDH in detecting Plasmodium vivax
Mean Mean
AL (%) Humasis (%) Parasitemia (/μL) pLDH (ng/mL)
(100.0) 40/40 (100.0) 6,265.1 ± 3,586.7 12,532.5 ± 6,286.6
(100.0) 59/59 (100.0) 5,118.9 ± 3,463.8 1,702.0 ± 1,001.5
(87.5) 14/16 (87.5) 1,613.4 ± 1,373.6 176.5 ± 105.7
(52.7) 19/37 (55.5) 722.1 ± 1344.6 13.5 ± 9.1
2 (85.5) 132/152 (86.8) 3,954.1 ± 3,712.5 3,971.5 ± 6,120.9
00 0/100 0 0
Figure 1 Correlations between parasitaemia and the levels of pLDH among isolated Plasmodium vivax patients with clinical symptoms.
Jang et al. Malaria Journal 2013, 12:181 Page 4 of 6
http://www.malariajournal.com/content/12/1/181provide more reliable analysis of selecting adequate mal-
aria RDTs.
Without adequate baseline data of pLDH levels from
clinically isolated P. vivax, it is difficult to correct the inter-
pretation of results to make better decisions for selectingTable 2 Limit of detection for pLDH in three rapid












5,000 8,700.0 100% 100% 100%
500 870.0 100% 100% 100%
250 435.0 100% 100% 100%
50 87.0 100% 100% 100%
25 44.0 100% 0% 100%
5 8.7 0% 0% 0%
0.5 0.9 0% 0% 0%
0 0 0% 0% 0%reliable malaria RDTs. Since none of the malaria RDTs de-
tect the parasite itself, the secreted biomarkers became the
diagnostic targets. To date, the level of target biomarkers
using a standardized protocol for clinically isolated malaria
samples are rarely reported [13].
Here, In this study, the distribution of pLDH in clinic-
ally isolated P. vivax samples, and the relationships be-
tween levels of pLDH and parasitaemia and between
levels of pLDH and sensitivities of pLDH-based RDTs areTable 3 The sensitivities of rapid diagnostic tests were
compared to the levels of pLDH in detecting Plasmodium
vivax infection
Mean Mean
RDT N Parasitaemia(/μL) pLDH (ng/mL)
All RDT Positive 130 4,586.1 ± 6,666.8 4,651.2 ± 6,374.1
2 RDT positive 3 777.7 ± 1076.5 5.0 ± 7.1
All RDT Negative 19 348.8 ± 602.4 19.7 ± 28.4
Total 152 3,954.1 ± 3,712.5 3,971.5 ± 6,120.9
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report, Humasis Malaria P.F/Pan Antigen test (AMAL-
7025) showed panel detection score (PDS) of 0% at both
200 and 2000 parasites/μL of P. vivax [14]. In addition,
false positive rate of Humasis kit was 97.8%. While the
performance parameter in this study was not PDS, but
clinical sensitivity, Humasis kit in this study demon-
strated the clinical sensitivity of 55.5 ~ 100.0% at similar
parasitaemia (Table 1). Next, specificity of Humasis kit for
P. vivax was 100% with no observed false positivity. As for
OptiMAL-IT kit (710024), round 4 report presented PDS
of 97.1 and 68.6% at 200 and 2,000 ~ 5,000 parasites/μL of
P. vivax, respectively. On the other hand, OptiMAL-IT
showed increased clinical sensitivity from 52.7 to 100%,
as the P. vivax parasitaemia increased. As for the SD
Bioline Malaria Ag P.f/Pan kit (05 F60), round 4 report
showed PDS of 97.1 and 100.0% at 200 and 2,000 ~
5,000 parasites/μL of P. vivax, respectively. However, SD
Bioline demonstrated slightly decreased clinical sensitivity
of 87.5 ~ 100.0% (Table 1). In this study, lower sensitivities
in all three RDTs were observed from groups with lower
pLDH antigen levels (Table 1). From the study for deter-
mining the limit of detection, lower levels pLDH associated
with lower sensitivities in all three RDTs (Table 2). These
direct correlations were similar to the levels of parasitaemia
in all three RDTs. Above results suggested the possibility of
pLDH, as a performance parameter for malaria RDTs. This
information on currently available RDTs is valuable in re-
vealing detection limits against pLDH. Therefore, the
current results could provide one more reasonable proto-
col for comparing various malaria RDTs and their practical
guidelines in developing sensitive malaria RDTs.
pLDH antigen ELISA system showed higher sensitivity
(95.4%) in comparison with three RDTs (85.5-86.8%),
which might be associated with the fact that ELISA uses
50 μL of blood, while RDTs used only 5–10 μL of blood.
RDTs are fast and convenient diagnostic tools. Parasit-
aemia levels of P. vivax in ROK ranged 2–25,000/μL
with mean level of 3,954.1 ± 3712.5/μL, while pLDH
levels of P. vivax ranged between 0–22,387 ng/mL with
mean value of 3,971.5 ± 6120.9 ng/mL. pLDH levels
showed moderate correlation with parasite density of
P. vivax, as determined by microscopy (r = 0.4, p < 0.05).
From three tested RDTs, pLDH levels and parasit-
aemia levels of three RDTs, positive cases were higher
than two RDT positive cases or all RDT negative cases.
One positive sample from two RDT tests (n = 3) showed
disparity between parasitaemia and pLDH levels, where
the pLDH and parasitaemia levels were 15 ng/mL and
2,300/μL, respectively. These levels of parasitaemia most
likely produce clinical symptoms. RDTs are fast and con-
venient diagnostic tools. Using only RDTs, malaria diagno-
sis might be difficult and patients might be left untreated,
leading to severe complications. Since the evaluation ofRDTs is currently based on patients’ parasitaemia levels,
with little information on targeted biomarkers in clinical
isolates, the current study provides additional information
for selecting adequate malaria RDT in fields.
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